These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21390518

  • 41. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL, del Muro XG.
    Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
    [Abstract] [Full Text] [Related]

  • 42. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
    Wu TJ, Lee LY, Yeh CN, Wu PY, Chao TC, Hwang TL, Jan YY, Chen MF.
    BMC Gastroenterol; 2006 Oct 24; 6():29. PubMed ID: 17062131
    [Abstract] [Full Text] [Related]

  • 43. Imatinib therapy after resection of high-risk gastrointestinal stromal tumors in Chinese patients: a median follow-up of 48 months.
    Lei C, Zhao B, Wang Q, Ge L, Wang H.
    J BUON; 2018 Oct 24; 23(2):460-467. PubMed ID: 29745093
    [Abstract] [Full Text] [Related]

  • 44. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
    Ogata K, Mochiki E, Ojima H, Haga N, Fukuchi M, Aihara R, Ando H, Uchida N, Toyomasu Y, Suzuki M, Kimura A, Kogure N, Yokobori T, Ohno T, Kuwano H.
    J Surg Oncol; 2014 Dec 24; 110(8):942-6. PubMed ID: 25164620
    [Abstract] [Full Text] [Related]

  • 45. Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.
    Sicklick JK, Lopez NE.
    J Gastrointest Surg; 2013 Nov 24; 17(11):1997-2006. PubMed ID: 23775094
    [Abstract] [Full Text] [Related]

  • 46. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
    Kanda T, Ishikawa T, Hirota S, Yajima K, Kosugi S, Ohashi M, Suzuki S, Mashima Y, Ajioka Y, Hatakeyama K.
    Jpn J Clin Oncol; 2012 Jul 24; 42(7):578-85. PubMed ID: 22523393
    [Abstract] [Full Text] [Related]

  • 47. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
    Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC.
    Surgery; 2003 Oct 24; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
    [Abstract] [Full Text] [Related]

  • 48. A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.
    Reece-Smith AM, MacGoey P, Shah MA, Leeder P, Andrew DR, McCulloch T, Parsons SL.
    Eur J Surg Oncol; 2012 Jun 24; 38(6):484-9. PubMed ID: 22342866
    [Abstract] [Full Text] [Related]

  • 49. Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate.
    Hamada M, Ozaki K, Horimi T, Tsuji A, Nasu Y, Iwata J, Nagata Y.
    Int J Clin Oncol; 2008 Aug 24; 13(4):355-60. PubMed ID: 18704638
    [Abstract] [Full Text] [Related]

  • 50. [Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].
    Heger U, Weitz J, Lordick F.
    Chirurg; 2008 Jul 24; 79(7):630-7. PubMed ID: 18548219
    [Abstract] [Full Text] [Related]

  • 51. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
    Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W.
    J Cancer Res Clin Oncol; 2007 Sep 24; 133(9):589-97. PubMed ID: 17458563
    [Abstract] [Full Text] [Related]

  • 52. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K, Sandvik OM, Søreide JA, Gudlaugsson E, Mangseth K, Haugland HK.
    Clin Transl Oncol; 2012 Aug 24; 14(8):619-29. PubMed ID: 22855146
    [Abstract] [Full Text] [Related]

  • 53. Emergence of secondary resistance to imatinib in recurrent gastric GIST.
    Jayanthi NV.
    J Gastrointest Surg; 2010 Dec 24; 14(12):2018-9; author reply 2020. PubMed ID: 20714935
    [No Abstract] [Full Text] [Related]

  • 54. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, Kim KH, Yook JH, Kim BS, Kang YK.
    J Surg Oncol; 2008 Jul 01; 98(1):27-33. PubMed ID: 18452195
    [Abstract] [Full Text] [Related]

  • 55. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.
    Blesius A, Cassier PA, Bertucci F, Fayette J, Ray-Coquard I, Bui B, Adenis A, Rios M, Cupissol D, Pérol D, Blay JY, Le Cesne A.
    BMC Cancer; 2011 Feb 15; 11():72. PubMed ID: 21324142
    [Abstract] [Full Text] [Related]

  • 56. Clinicopathologic characteristics of gastrointestinal stromal tumor of the stomach.
    Yang HK, Park DJ, Lee HJ, Kim HH, Kim WH, Lee KU.
    Hepatogastroenterology; 2008 Feb 15; 55(86-87):1925-30. PubMed ID: 19102424
    [Abstract] [Full Text] [Related]

  • 57. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG.
    J Surg Oncol; 2011 Dec 15; 104(7):760-4. PubMed ID: 21713778
    [Abstract] [Full Text] [Related]

  • 58. [Efficacy and prognosis of different treatments on 63 patients with small intestinal gastrointestinal stromal tumors].
    Liu L, Liu Y, Wu X, Chen L, Xu W.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr 15; 17(4):344-7. PubMed ID: 24760642
    [Abstract] [Full Text] [Related]

  • 59. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.
    Anticancer Drugs; 2008 Jul 15; 19(6):607-12. PubMed ID: 18525320
    [Abstract] [Full Text] [Related]

  • 60. Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10  cm: A Single-Institution Experience in China.
    Shen C, Chen H, Yin Y, Chen J, Tang S, Zhang B, Han L, Chen Z, Chen J.
    Medicine (Baltimore); 2015 Jul 15; 94(28):e1117. PubMed ID: 26181546
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.